ArticleNeurology and therapy2026
Real-World Effectiveness and Tolerability of Rimegepant as Second- or Third-Line Acute Treatment for Migraine: A Prospective Observational Study.
Takafumi Tanei et al.PubMed ↗Publisher ↗
No numbers read from the abstract.